Red Light Ptosis Proof-of-Concept

Launched by UNIVERSITY COLLEGE, LONDON · Feb 27, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Red Light Ptosis Proof-of-Concept, is testing a new treatment aimed at helping children and young people with droopy eyelids (called ptosis) and eye movement issues, like squinting, caused by certain genetic conditions known as mitochondrial diseases. The treatment involves shining a red light through the closed eyelid for just 3 minutes each day. The study will last for 18 months, and researchers hope this treatment will strengthen the eyelid muscles, making it easier for participants to open their eyes and potentially improve squinting.

To be eligible for this trial, participants must be between the ages of 3 and 17 and have a confirmed genetic diagnosis of primary mitochondrial disease, which means they have specific genetic changes that affect their energy production. The study is open to all genders. Children who do not have the correct genetic diagnosis or are unable to follow the treatment plan will not be able to participate. If accepted, participants can expect to take part in daily light treatment and regular eye assessments to monitor their progress. This is an exciting opportunity for those affected by these conditions, as it may lead to new ways to improve their quality of life.

Gender

ALL

Eligibility criteria

• • Inclusion: Age 3 to less than 18 years Genetically confirmed diagnosis of primary mitochondrial disease (known pathogenic mutation(s) in mitochondrial or nuclear DNA known to cause primary mitochondrial disease) Ptosis
• • Exclusion: Genetic diagnosis not consistent with primary mitochondrial disease. No genetic diagnosis Unable to cooperate with light treatment or ophthalmological assessments.